Charcot neuroosteoarthropathy (CN) is considered a rare complication of diabetic neuropathy. Due to its insidious mode of presentation, CN may be difficult to diagnose timely and a high index of suspicion is required from both, the diabetic patient (especially those with neuropathy) and their physicians for the early diagnosis and treatment to prevent major complications.
Methods
We planned a narrative review and searched MEDLINE database to identify evidence regarding CN incidence, treatment options, and recent guidelines. As practitioners do not commonly treat CN, a characteristic clinical case is also presented.
Results
The available evidence for diagnosis and treatment remains of low quality. On the one hand, there is an urgent need for action to increase awareness of the disease in both practitioners and people with diabetes. On the other hand, prospective nationwide registries of patients with diabetic neuropathy will help clarify the prognostic factors that may predispose to this complication, and more randomized clinical trials are needed to identify whether medical treatment may improve CN outcomes. For the time being, offloading of the foot to stop the perpetuation of trauma, and inflammation, and importantly to arrest the progression to a deformed nonfunctional foot is the cornerstone of medical therapy of CN. Multidisciplinary assessment between diabetologists and radiologists is fundamental for prompt diagnosis.
Conclusions
To avoid potentially deleterious delays in diagnosis and treatment, every physician should bear in mind that every patient with diabetic neuropathy presenting with a warm swollen foot should be treated as having CN until proven otherwise.
CharcotJ. Sur quelques arthropathies qui paraissent dépendre d’une lesion du cerveau ou de la moelle épinière. Arch Des Phys Norm Path. 1868;1:161-178.
2.
JordanW. Neuritic manifestations in diabetes mellitus. Arch Intern Med. 1936;57:307-358.
3.
PetrovaNLFosterAVMEdmondsME. Difference in presentation of Charcot osteoarthropathy in type 1 compared with type 2 diabetes. Diabetes Care. 2004;27(5):1235-1236.
4.
JulienC-AHa VanGM’BembaJ, et al.Real-world treatment patterns and diagnosis of Charcot foot in franco-Belgian diabetic foot expert centers (the EPiChar study). Acta Diabetol. 2023;60(9):1209-1218.
5.
WukichDKSadoskasDVaudreuilNJFourmanM. Comparison of diabetic Charcot patients with and without foot wounds. Foot Ankle Int. 2017;38(2):140-148.
6.
SvendsenOLRabeOCWinther-JensenMAllinKH. How common is the rare Charcot foot in patients with diabetes?Diabetes Care. 2021;44(4):e62-e63.
7.
O’LoughlinAKellegherEMcCuskerCCanavanR. Diabetic Charcot neuroarthropathy: prevalence, demographics and outcome in a regional referral centre. Ir J Med Sci. 2017;186(1):151-156.
8.
AnichiniRPolicardoLLombardoFL, et al.Hospitalization for Charcot neuroarthropathy in diabetes: a population study in Italy. Diabetes Res Clin Pract. 2017;129:25-31.
9.
KorstGSRatliffHTTorianJJimohROJupiterDC. Delayed diagnosis of Charcot foot: a systematic review. J Foot Ankle Surg. 2022;61(5):1109-1113.
10.
RogersLCFrykbergRGArmstrongDG, et al.The Charcot foot in diabetes. Diabetes Care. 2011;34(9):2123-2129.
11.
LamJAbu-AmerYNelsonCAFremontDHRossFPTeitelbaumSL. Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. Ann Rheum Dis. 2002;61(suppl 2):ii82-ii83.
12.
MabilleauGPetrovaNLEdmondsMESabokbarA. Increased osteoclastic activity in acute Charcot’s osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia. 2008;51(6):1035-1040.
13.
GerstenfeldLCChoTJKonT, et al.Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Organs. 2001;169(3):285-294.
14.
JeffcoateWJGameFCavanaghPR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet (London, England). 2005;366(9502):2058-2061.
15.
BoyleWJSimonetWSLaceyDL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337-342.
16.
Korzon-BurakowskaAJakóbkiewicz-BaneckaJFiedosiukA, et al.Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy. Diabet Med. 2012;29(6):771-775.
17.
PitoccoDZelanoGGioffrèG, et al.Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic Charcot neuroarthropathy: a case-control study. Diabetes Care. 2009;32(9):1694-1697.
18.
Bruhn-OlszewskaBKorzon-BurakowskaAWęgrzynGJakóbkiewicz-BaneckaJ. Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers for Charcot arthropathy development. Sci Rep. 2017;7(1):501.
19.
YoungMJMarshallAAdamsJESelbyPLBoultonAJ. Osteopenia, neurological dysfunction, and the development of Charcot neuroarthropathy. Diabetes Care. 1995;18(1):34-38.
20.
PetrovaNLFosterAVMEdmondsME. Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between type 1 and type 2 diabetes. Diabet Med. 2005;22(6):756-761.
21.
PetrovaNLEdmondsME. A prospective study of calcaneal bone mineral density in acute Charcot osteoarthropathy. Diabetes Care. 2010;33(10):2254-2256.
22.
DardariD. An overview of Charcot’s neuroarthropathy. J Clin Transl Endocrinol. 2020;28:22:100239.
23.
MatricaliGABammensBKuypersDFlourMMathieuC. High rate of Charcot foot attacks early after simultaneous pancreas-kidney transplantation. Transplantation. 2007;83(2):245-246.
24.
García BarradoFKuypersDRMatricaliGA. Charcot neuroarthropathy after simultaneous pancreas-kidney transplantation: risk factors, prevalence, and outcome. Clin Transplant. 2015;29(8):712-719.
25.
EdmondsMERobertsVCWatkinsPJ. Blood flow in the diabetic neuropathic foot. Diabetologia. 1982;22(1):9-15.
26.
JeffcoateWGameF. The Charcot foot reflects a response to injury that is critically distorted by preexisting nerve damage: an imperfect storm. Diabetes Care. 2022;45(7):1691-1697.
27.
NóbregaMdMArasRNettoEM, et al.Risk factors for Charcot foot. Arch Endocrinol Metab. 2015;59(3):226-230.
28.
MeloniMAhluwaliaRBelliaA, et al.The neuro-ischaemic Charcot foot: prevalence, characteristics and severity of peripheral arterial disease in acute Charcot neuro-arthropathy. J Clin Med. 2022;11(21):6230.
29.
WukichDKRaspovicKMSuderNC. Prevalence of peripheral arterial disease in patients with diabetic Charcot neuroarthropathy. J Foot Ankle Surg. 2016;55(4):727-731.
30.
Edelman SVKosofskyEMPaulRAKozakGP. Neuro-osteoarthropathy (Charcot’s joint) in diabetes mellitus following revascularization surgery. Three case reports and a review of the literature. Arch Intern Med. 1987;147(8):1504-1508.
31.
PalenaLMBroccoENinkovicSVolpeAManziM. Ischemic Charcot foot: different disease with different treatment?J Cardiovasc Surg (Torino). 2013;54(5):561-566.
32.
PetrovaNLMonizCEliasDABuxton-ThomasMBatesMEdmondsME. Is there a systemic inflammatory response in the acute Charcot foot?Diabetes Care. 2007;30(4):997-998.
33.
PetrovaNLDewTKMustoRL, et al.Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy. Diabet Med. 2015;32(2):267-273.
34.
FolestadAÅlundMAstebergS, et al.IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year follow-up study. J Foot Ankle Res. 2015;8:39.
35.
RaspovicKMSchaperNCGoodayC, et al. Diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus: a systematic review. Diabetes Metab Res Rev.2024:40(3):e3653. Published online.
36.
BrodskyJWRouseAM. Exostectomy for symptomatic bony prominences in diabetic Charcot feet. Clin Orthop Relat Res. 1993;296:21-26.
37.
TrepmanENihalAPinzurMS. Current topics review: Charcot neuroarthropathy of the foot and ankle. Foot Ankle Int. 2005;26(1):46-63.
38.
ShibataTTadaKHashizumeC. The results of arthrodesis of the ankle for leprotic neuroarthropathy. J Bone Joint Surg Am. 1990;72(5):749-756.
39.
ChantelauEPollLW. Evaluation of the diabetic Charcot foot by MR imaging or plain radiography—an observational study. Exp Clin Endocrinol Diabetes. 2006;114(8):428-431.
40.
SchonLCEasleyMEWeinfeldSB. Charcot neuroarthropathy of the foot and ankle. Clin Orthop Relat Res. 1998;349:116-131.
41.
RosskopfABLoupatatzisCPfirrmannCWABöniTBerliMC. The Charcot foot: a pictorial review. Insights Imaging. 2019;10(1):77.
42.
SinhaSMunichoodappaCSKozakGP. Neuro-arthropathy (Charcot joints) in diabetes mellitus (clinical study of 101 cases). Medicine (Baltimore). 1972;51(3):191-210.
43.
MautoneMNaidooP. What the radiologist needs to know about Charcot foot. J Med Imaging Radiat Oncol. 2015;59(4):395-402.
44.
Martín NoguerolTLuna AlcaláABeltránLSGómez CabreraMBroncano CabreroJVilanovaJC. Advanced MR imaging techniques for differentiation of neuropathic arthropathy and osteomyelitis in the diabetic foot. Radiographics. 2017;37(4):1161-1180.
45.
LauriCTammingaMGlaudemansAWJM, et al.Detection of osteomyelitis in the diabetic foot by imaging techniques: a systematic review and meta-analysis comparing MRI, white blood cell scintigraphy, and FDG-PET. Diabetes Care. 2017;40(8):1111-1120.
46.
GriffithsDAKaminskiMR. Duration of total contact casting for resolution of acute Charcot foot: a retrospective cohort study. J Foot Ankle Res. 2021;14(1):44.
47.
TongeXNWidnallJCJacksonGPlattS. A ten-year retrospective study investigating the rate of venous thromboembolism in patients who require immobilization in a total contact lower limb cast. Bone Joint J. 2019;101-B(6):691-694.
48.
DasLBhansaliAPrakashMJudeEBRastogiA. Effect of methylprednisolone or zoledronic acid on resolution of active Charcot neuroarthropathy in diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2019;42(12):e185-e186.
49.
Busch-WestbroekTEDelpeutKBalmR, et al.Effect of single dose of RANKL antibody treatment on acute Charcot neuro-osteoarthropathy of the foot. Diabetes Care. 2018;41(3):e21-e22.
50.
WukichDKFrykbergRGKavarthapuV. Charcot neuroarthropathy in persons with diabetes: it’s time for a paradigm shift in our thinking.Diabetes Metab Res Rev2024;40(3):e3754.
51.
SimonSRTejwaniSGWilsonDLSantnerTJDennistonNL. Arthrodesis as an early alternative to nonoperative management of Charcot arthropathy of the diabetic foot. J Bone Joint Surg Am. 2000;82-A(7):939-950.
52.
RamanujamCLStutoACZgonisT. Surgical treatment of midfoot Charcot neuroarthropathy with osteomyelitis in patients with diabetes: a systematic review. J Wound Care. 2020;29(Sup6):S19-S28.
53.
Dalla PaolaLBaldazziGGabelliniT, et al. Circular external fixation as a new offloading standard of treatment in Charcot neuro-osteoarthropathy complicated by midfoot osteomyelitis: a pilot, prospective case-control study. Int J Low Extrem Wounds. 2023:15347346231185404. Published online.
54.
GazisAPoundNMacfarlaneRTreeceKGameFJeffcoateW. Mortality in patients with diabetic neuropathic osteoarthropathy (Charcot foot). Diabet Med. 2004;21(11):1243-1246.
55.
WukichDKSchaperNCGoodayC, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes Metab Res Rev. 2024:40(3);e3646.
56.
MetcalfLMusgroveMBentleyJ, et al.Prevalence of active Charcot disease in the east midlands of England. Diabet Med. 2018;35(10):1371-1374.
57.
SchmidtBMWrobelJSHolmesCM. Physician knowledge of a rare foot condition—influence of diabetic patient population on self-described knowledge and treatment. Clin Diabetes Endocrinol. 2017;3:2.
58.
BoultonAJMWhitehouseRW. The Diabetic Foot. In: FeingoldKRAnawaltBBlackmanMR, et al., eds. 2000.
